Inhibrx Biosciences(INBX.US)

Last Updated 19:00:00 ET
longbridge loading

Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)

Tip Ranks·
US
INBX
-1.94%
US
PBE
+0.33%
US
SBIO
+1.57%
Tip Ranks·
US
INBX
-1.94%
US
PBE
+0.33%
US
SBIO
+1.57%

Inhibrx Reports First Quarter 2026 Financial Results | INBX Stock News

StockTitan·
US
INBX
-1.94%
US
PBE
+0.33%
US
LABU
+1.66%
StockTitan·
US
INBX
-1.94%
US
PBE
+0.33%
US
LABU
+1.66%

Top 10 US Stock Losers (5.12)

Top Gainers&Losers·
US
PSIX
+6.33%
US
GTM
-4.50%
US
DXYZ
+21.40%
Top Gainers&Losers·
US
PSIX
+6.33%
US
GTM
-4.50%
US
DXYZ
+21.40%

Inhibrx announces positive interim results from HexAgon trial

WorldPharmaceuticals·
US
INBX
-1.94%
US
BIB
+0.08%
US
XBI
+0.63%
WorldPharmaceuticals·
US
INBX
-1.94%
US
BIB
+0.08%
US
XBI
+0.63%

Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Market Beat·
US
INBX
-1.94%
US
MRK
+1.99%
US
PBE
+0.33%
Market Beat·
US
INBX
-1.94%
US
MRK
+1.99%
US
PBE
+0.33%

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | INBX Stock News

StockTitan·
US
INBX
-1.94%
US
BBH
+0.63%
US
LABU
+1.66%
StockTitan·
US
INBX
-1.94%
US
BBH
+0.63%
US
LABU
+1.66%
© 2026 Longbridge｜Disclaimer